Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Manitex Capital Inc. (V:MNX)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for MNX within the last 6 months
See all filings within the past 6 months

Company News

Jun 30, 2020 22:00 ET
Manitex Capital Inc. Restates Previously Reported Q1 2020 Quarterly Financial Results and Grants Options to Certain Directors
KIRKLAND, QC, June 30, 2020 /CNW Telbec/ - Manitex Capital Inc. ("Manitex" or the "Company") announced today that it has filed a restatement of its previously reported financial results for January 31, 2020, together with a revised management discussion and analysis ("MD&A") for the quarter.  The restatement was required due to an error in the calculation of the Deferred Tax Liability.  The restated financial statements and revised MD&A are available on SEDAR at
Read full article
Oct 10, 2019 02:17 ET
Early Warning Report Filed Pursuant To National Instrument 62-103
This press release is being disseminated as required by National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 20218720
Feb 15, 20211210
Jan 15, 202110,32110,000
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Manitex Capital Inc. is a Canada-based company that specializes in acquiring interests in companies and participates in increasing shareholder value in these businesses. The Company operates through three segments: diversified investments (investment), biotechnology (biotech) and a pharmaceutical business (pharma). The investment segment holds interests in companies in the life science industry and also invests in marketable securities. Through its subsidiary, ANRis Pharmaceuticals Inc. (ANRis), (the biotechnology segment), the Company specializes in development of the delivery of nucleic acids for therapeutic purposes. Through its subsidiary, Valeo Pharma Inc. (Valeo), (the pharmaceutical segment), the Company acquires and markets specialty pharmaceutical products and also markets and distributes third-party pharmaceutical products. VPI Pharmaceuticals Inc. is the subsidiary of the Valeo.

See business summary



Search (past week) for $MNX.CA MNX.V

  • No tweets found